• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Planet Labs Shares Are Trading Higher; Here Are 28 Stocks Moving Premarket

    12/15/22 6:23:53 AM ET
    $ABCL
    $AIRS
    $ALIT
    $AMAM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ABCL alert in real time by email

    Gainers

    • Scopus BioPharma Inc. (NASDAQ:SCPS) shares rose 74.7% to $0.4104 in pre-market trading after declining 4% on Wednesday.
    • Surrozen, Inc. (NASDAQ:SRZN) shares rose 67.3% to $0.7291 in pre-market trading. The company, last month, posted a narrower Q3 loss.
    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) rose 54.1% to $0.2366 in pre-market trading after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
    • Core Scientific, Inc. (NASDAQ:CORZ) rose 53% to $0.3826 in pre-market trading after B. Riley Financial issued an open letter to Core Scientific shareholders and lenders.
    • Jounce Therapeutics, Inc. (NASDAQ:JNCE) shares rose 23.4% to $0.8499 in pre-market trading. Jounce Therapeutics recently presented INNATE Phase 1 and SELECT clinical trial data at the European Society of Medical Oncology Immuno-Oncology Annual Congress.
    • Gritstone bio, Inc. (NASDAQ:GRTS) rose 14.8% to $4.50 in pre-market trading after jumping 26% on Wednesday. Gritstone bio was recently granted two new US patents for self-amplifying mRNA.
    • E-Home Household Service Holdings Limited (NASDAQ:EJH) rose 12.2% to $0.5796 in pre-market trading after gaining 6% on Wednesday.
    • Sio Gene Therapies Inc (NASDAQ:SIOX) rose 11.6% to $0.40 in pre-market trading. On December 14, 2022, the company’s board unanimously approved the dissolution and liquidation of the company pursuant to a plan of complete liquidation and dissolution.
    • Quotient Limited (NASDAQ:QTNT) rose 11.1% to $0.35 in pre-market trading after dropping 8% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market.
    • Nogin, Inc. (NASDAQ:NOGN) rose 10.3% to $0.8998 in pre-market trading after declining around 7% on Wednesday.
    • Getaround, Inc. (NYSE:GETR) rose 9.3% to $1.06 in pre-market trading after dipping 29% on Wednesday. Getaround recently announced closing of business combination with InterPrivate II Acquisition Corp.
    • Cosmos Holdings Inc. (NASDAQ:COSM) shares rose 9.2% to $0.3495 in pre-market trading after jumping 14% on Wednesday.
    • Athersys, Inc. (NASDAQ:ATHX) rose 8.7% to $0.95 in pre-market trading after surging over 10% on Wednesday. Athersys, last month, posted a Q3 loss of $1.15 per share.
    • AbCellera Biologics Inc. (NASDAQ:ABCL) rose 7.1% to $10.85 in pre-market trading.
    • Planet Labs PBC (NYSE:PL) rose 3.3% to $5.38 in pre-market trading after the company reported better-than-expected financial results for its third quarter and issued strong full-year revenue guidance.


    Don’t forget to check out our premarket coverage here .


    Losers

    • Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) fell 19.4% to $0.4150 in pre-market trading. Vallon Pharmaceuticals shares jumped around 105% on Wednesday after the company and GRI Bio announced they entered into a merger agreement.
    • GlycoMimetics, Inc. (NASDAQ:GLYC) shares fell 17.2% to $1.83 in pre-market trading.
    • Drive Shack Inc. (NYSE:DS) shares fell 15% to $0.2039 in pre-market trading. Drive Shack shares dropped around 50% on Wednesday after the company announced the intention to voluntarily delist and deregister its securities.
    • Meiwu Technology Company Limited (NASDAQ:WNW) fell 10.8% to $2.32 in pre-market trading after surging 41% on Wednesday.
    • Novavax, Inc. (NASDAQ:NVAX) shares fell 10% to $15.51 in pre-market trading. Novavax proposed an underwritten public offering to sell up to $125 million of its common stock.
    • BIMI International Medical, Inc. (NASDAQ:BIMI) fell 9.2% to $2.57 in pre-market trading after climbing 36% on Wednesday. BIMI reported entry into a material definitive agreement for the acquisition of Wuzhou Qiangsheng Hospital Co., Ltd., Suzhou Eurasia Hospital Co., Ltd. and Yunan Yuxi Minkang Hospital Co., Ltd.
    • Alight, Inc. (NYSE:ALIT) fell 9.2% to $8.15 in pre-market trading. Alight, last week, announced the acquisition of ReedGroup.
    • AirSculpt Technologies, Inc. (NASDAQ:AIRS) shares fell 8.5% to $3.00 in pre-market trading.
    • Icosavax, Inc. (NASDAQ:ICVX) fell 8.4% to $8.16 in pre-market trading. Icosavax shares jumped 112% on Wednesday after the company provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against respiratory syncytial virus.
    • Bird Global, Inc. (NYSE:BRDS) fell 7.7% to $0.19 in pre-market trading.
    • Yumanity Therapeutics, Inc. (NASDAQ:YMTX) fell 7.6% to $1.55 in pre-market trading after dropping 17% on Wednesday. Yumanity Therapeutics, last week, declared a special dividend in connection with the proposed asset sale to Janssen and merger with Kineta.
    • Ambrx Biopharma Inc. (NYSE:AMAM) fell 7.5% to $1.98 in pre-market trading after gaining 5% on Wednesday.
    • Tesla, Inc. (NASDAQ:TSLA) fell 2.7% to $152.57 in pre-market trading. Tesla CEO Elon Musk sold around $3.6 billion worth of shares in the company, according to a Securities and Exchange Commission filing.
    Get the next $ABCL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABCL
    $AIRS
    $ALIT
    $AMAM

    CompanyDatePrice TargetRatingAnalyst
    Tesla Inc.
    $TSLA
    3/4/2026$460.00Buy
    BofA Securities
    Core Scientific Inc.
    $CORZ
    3/3/2026$23.00Hold → Buy
    Needham
    Alight Inc.
    $ALIT
    2/20/2026$1.00Buy → Neutral
    Citigroup
    Alight Inc.
    $ALIT
    2/19/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    Alight Inc.
    $ALIT
    2/19/2026Buy → Hold
    Needham
    Surrozen Inc.
    $SRZN
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    Alight Inc.
    $ALIT
    2/17/2026$1.40Underperform
    BofA Securities
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    More analyst ratings

    $ABCL
    $AIRS
    $ALIT
    $AMAM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ABCL
    $AIRS
    $ALIT
    $AMAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on Tesla with a new price target

    BofA Securities resumed coverage of Tesla with a rating of Buy and set a new price target of $460.00

    3/4/26 8:40:18 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Core Scientific upgraded by Needham with a new price target

    Needham upgraded Core Scientific from Hold to Buy and set a new price target of $23.00

    3/3/26 10:31:14 AM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Alight downgraded by Citigroup with a new price target

    Citigroup downgraded Alight from Buy to Neutral and set a new price target of $1.00

    2/20/26 8:21:34 AM ET
    $ALIT
    Real Estate

    $ABCL
    $AIRS
    $ALIT
    $AMAM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weiss Eric Stanton bought $101,700 worth of shares (7,000 units at $14.53), increasing direct ownership by 3% to 252,262 units (SEC Form 4)

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    3/10/26 4:08:53 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Large owner Chernett Jorey bought $91,200 worth of shares (45,600 units at $2.00), increasing direct ownership by 0.72% to 6,398,211 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/9/26 8:40:24 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $192,900 worth of shares (110,000 units at $1.75), increasing direct ownership by 2% to 6,352,611 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/4/26 6:58:41 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $ABCL
    $AIRS
    $ALIT
    $AMAM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000

    CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into a Letter of Intent ("LOI"), through its wholly owned subsidiary CosmoFarm S.A. ("CosmoFarm"), with respect to the acquisition of an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market for almost 40 years. The term of the LOI is ninety (90) days from March 6, 2026. The network currently generates approximately €10 million (approximately $11.5 million based on the prevailing EUR/USD exchange rate) in annual gross reve

    3/10/26 9:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Alight Expands Partner Network with the Additions of nudge and Benifex

    Alight, Inc. (NYSE:ALIT), a leading benefits administration provider of health, wealth, leave and point solutions, today announced the expansion of its Alight Partner Network with the addition of nudge Global and Benifex, two UK-based, global partners that strengthen Alight's financial wellbeing and total rewards capabilities for multinational employers. The Alight Partner Network offers a curated ecosystem of solutions designed to help employers deliver a more connected and engaging employee experience. With the addition of nudge and Benifex, Alight continues to expand its global partner ecosystem, enabling large, multinational clients to access trusted financial wellbeing and global ben

    3/10/26 8:30:00 AM ET
    $ALIT
    Real Estate

    Cadillac Formula 1® Team Joins Forces with Core Scientific as Official Data Center Partner

    Core Scientific and Cadillac Formula 1® Team Announce a Multi-Year Global Partnership Core Scientific, Inc. (NASDAQ:CORZ) ("Core Scientific" or the "Company"), a leader in digital infrastructure for high-density colocation, and Cadillac Formula 1® Team have announced a multi-year global partnership, naming Core Scientific as the team's Official Data Center Partner. Core Scientific will play a central role in advising and shaping the team's data center infrastructure in its new U.S. headquarters, currently under construction in Indianapolis, Indiana. Through this partnership, Core Scientific will provide strategic consulting, architectural guidance and optimization expertise to ensure th

    3/10/26 8:00:00 AM ET
    $CORZ
    Finance: Consumer Services
    Finance

    $ABCL
    $AIRS
    $ALIT
    $AMAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weiss Eric Stanton bought $101,700 worth of shares (7,000 units at $14.53), increasing direct ownership by 3% to 252,262 units (SEC Form 4)

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    3/10/26 4:08:53 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Chief Financial Officer Taneja Vaibhav converted options into 6,538 shares and sold $899,077 worth of shares (2,264 units at $397.03), increasing direct ownership by 31% to 18,106 units (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    3/9/26 7:00:14 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    EVP, CFO and Treasurer Kelly James Patrick converted options into 12,223 shares and covered exercise/tax liability with 5,904 shares, increasing direct ownership by 5% to 130,599 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/9/26 6:13:36 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABCL
    $AIRS
    $ALIT
    $AMAM
    SEC Filings

    View All

    SEC Form 144 filed by Tesla Inc.

    144 - Tesla, Inc. (0001318605) (Subject)

    3/6/26 5:42:03 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Core Scientific Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Core Scientific, Inc./tx (0001839341) (Filer)

    3/6/26 4:13:50 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    SEC Form S-8 filed by Alight Inc.

    S-8 - Alight, Inc. / Delaware (0001809104) (Filer)

    3/6/26 7:45:40 AM ET
    $ALIT
    Real Estate

    $ABCL
    $AIRS
    $ALIT
    $AMAM
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    BluSky AI Inc. Appoints Riley Cooney as Corporate Development and Strategy Officer

    Salt Lake City Utah, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BluSky AI Inc. (OTCID: BSAI), a leading developer of prefabricated modular AI infrastructure and Neocloud GPU-as-a-Service infrastructure, proudly announces the appointment of Riley Cooney as its Corporate Development and Strategy Officer. Cooney is a well-respected FP&A and strategic finance executive whose experience includes leadership through a $4B IPO in BTC and Hyperscale infrastructure. Riley has advised on AI and HPC data-center strategy, serving global institutional and Wall Street clients over the past two years. During his five years at Core Scientific (NASDAQ:CORZ), Riley helped scale revenue 24× while growing power capaci

    12/9/25 1:37:56 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Scientists Pointing to Hidden Power Source That Could Reshape Future of AI

    This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it

    12/3/25 8:30:00 AM ET
    $AMZN
    $AVGO
    $META
    Catalog/Specialty Distribution
    Consumer Discretionary
    Semiconductors
    Technology

    $ABCL
    $AIRS
    $ALIT
    $AMAM
    Financials

    Live finance-specific insights

    View All

    Core Scientific Announces Fourth Quarter Fiscal Year 2025 Results

    Key Highlights New Top-market Site: Announced an agreement to expand into Hunt County, Texas, which is expected to support ~430 MW of gross power capacity, with an approved ERCOT interconnection ramp schedule. Power Expansion at Existing Locations: Increased gross power capacity by ~300 MW across Dalton, Georgia and Pecos, Texas. Continued Execution on CoreWeave Contract: To date, energized ~350 MW of power and remain on track to deliver ~590 MW by early 2027. Core Scientific, Inc. (NASDAQ:CORZ), a leader in digital infrastructure for high-density colocation services, today announced financial results for the fourth quarter of 2025. "We're now past the halfway point on our e

    3/2/26 4:10:00 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AbCellera Reports Full Year 2025 Business Results

    AbCellera (NASDAQ:ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2025, AbCellera successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the year with approximately $700 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "We entered 2026 with a fully built platform, a growing pipeline with multiple potential first-in-class programs and important near-term clinical readouts, and sufficient liquidity to fund well beyond the next three years of p

    2/24/26 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    $AIRS
    $ALIT
    $AMAM
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    $AIRS
    $ALIT
    $AMAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Alight Inc.

    SC 13D/A - Alight, Inc. / Delaware (0001809104) (Subject)

    12/10/24 4:00:22 PM ET
    $ALIT
    Real Estate

    Amendment: SEC Form SC 13D/A filed by Alight Inc.

    SC 13D/A - Alight, Inc. / Delaware (0001809104) (Subject)

    12/5/24 4:51:02 PM ET
    $ALIT
    Real Estate

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care